DiRROS repository
CGRP-om inducirana glavobolja i hemodinamski odgovor kao predskazatelj terapije zasovane na CGRP antagonizmu
By Marjan Zaletel.
Abstract
Migraine is increasingly recognized as a disorder of the calcitonin gene-related peptide (CGRP) pathway. However, other factors are involved in migraine pathophysiology such as vasoactive intestinal peptide (VIP) and PACAP-38. Indeed, the CGRP-test can discriminate migraine from non-migraine and other non-CGRP induced migraine using CGRP-induced headache (CGRP-IH) and cerebral hemodynamic changes. Recent studies support the evidence of CGRP susceptible migraine prone to CGRP antagonism. Therefore, the CGRP-test may have an important role in therapeutic decisions regarding anti-CGRP monoclonal antibodies and gepants. This may improve the clinical effects of CGRP antagonism in migraine patients and increase therapeutic adherence. From the perspective of pain medicine may improve placebo response which can enhance favourable therapeutic outcomes.
Keywords
- Migraine and Headache Studies
- Migraine
- Calcitonin gene-related peptide
- Pathophysiology
- Placebo
- Calcitonin
- Sumatriptan
- Therapeutic effect
- Open access
Source
Published in DiRROS repository (University of Maribor). The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.